Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report.
JHEP Rep. 2019 Apr 11;1(1):66-69. doi: 10.1016/j.jhepr.2019.02.001. eCollection 2019 May.
JHEP Rep. 2019.
PMID: 32039353
Free PMC article.
No abstract available.